Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Santen Agrees with Nippon Organon to Develop, Manufacture, Market Glaucoma Treatment
January 29, 2001
-
ARCHIVE Novartis 5-Generation Campaign Recruits 378 Families
January 29, 2001
-
ARCHIVE Sankyo Completes Purchase of Sankyo Parke Davis Stocks from Pfizer
January 29, 2001
-
ARCHIVE WHO GLs for Allergic Rhinitis Introduced at UCB Symposium
January 29, 2001
-
ARCHIVE Kuraya Sanseido Aims at Sales of \1.5 Trillion in Next Stage
January 29, 2001
-
ARCHIVE BI Establishes Virtual Research Institute of Aging
January 29, 2001
-
ARCHIVE EMA Dissatisfied with FPMAJ Policy Regarding Healthcare Reform
January 29, 2001
-
ARCHIVE RESEARCH AND DEVELOPMENT NEWS IN BRIEF
January 29, 2001
-
ARCHIVE Yoshitomiyakuhin to Increase Market Share for Antipsychotic Drugs
January 29, 2001
-
ARCHIVE Major Analysts See Matsumotokiyoshi as No. 1 Drugstore Chain Operator
January 29, 2001
-
ARCHIVE BUSINESS NEWS IN BRIEF
January 29, 2001
-
ARCHIVE NHI Program Suffers from Ordinary Loss of \119 Bil. in 1999
January 29, 2001
-
ARCHIVE Tsuruha: Full-year Sales to Total \80.9 Bil.
January 29, 2001
-
ARCHIVE Fujirebio: Net Loss due to New Retirement Allowance Accounting
January 29, 2001
-
ARCHIVE Meiji Seika to Strengthen Its Overseas Business Structures: Vice President Ogawa
January 29, 2001
-
ARCHIVE PAJ President Uehara Stresses Importance of Self-medication
January 29, 2001
-
ARCHIVE National Burden Rate Can Be Reduced 10% Through Reform: Koseisho Study Team
January 29, 2001
-
ARCHIVE Council to Study Ways to Supply Drug Information to Public
January 29, 2001
-
ARCHIVE Jovi to Increase Its Member Stores to 3,000
January 29, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF
January 29, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…